Seoul – October 12, 2026 -- Parkinson's patients taking the investigational drug solengepras gained an average of 36 more minutes of "good" movement time per day than those on their regular medication alone, and the drug will now be submitted to the U.S. Food and Drug Administration for approval.
ARISE trial results presented at the MDS International Congress
The data from the ARISE clinical trial were presented at the International Congress of Parkinson's Disease and Movement Disorders. Patients, who can have difficulty moving, also reported improvements in measures of daily living, according to the source.
Patient-reported outcomes were positive across all measured areas of daily living. Drooling and saliva control showed the most significant self-reported change, while improved daytime sleepiness was also recorded.
Self-reported gains exceed what the on-time difference would predict
Ron Postuma, Chair of the MDS International Congress Scientific Program Committee, said the self-reported improvements are higher than would be expected for a 36-minute difference in "on" time. He said this indicates there is more to explore about the drug's possibilities.
Novel mechanism may open path for follow-on therapies
Solengepras works differently than other drugs currently on the market. Its progress could therefore open the door to further innovations using similar techniques, according to the source.
The source does not disclose a filing date, trial size, safety data or the sponsor company.